Sponsor RTCT Comments Show AI Enters Trials Through Data Plumbing First
Industry comment letters on FDA real time clinical trials show sponsors want AI in reconciliation and surveillance first, with human review gates on dose and safety decisions.
What changed
Analysis of Request for Information responses on FDA Real Time Clinical Trials (RTCT) shows major sponsors drawing the same line: AI assists qualified clinical judgment; it does not autonomously escalate doses or make safety calls. Comment letters from firms including Novartis, Lilly, Bayer, and Daiichi emphasize validation, audit trails, and data lineage over model sophistication.
FDA's 28 April 2026 announcement launched proof of concept RTCT streams with AstraZeneca and Amgen and sought input on a broader AI enabled early phase pilot. The agency extended the comment window through 29 June 2026 and signaled pilot selection criteria would follow in July with participant picks in August.
Why it matters
Biotech R&D leaders often ask when AI will choose trial paths. Sponsor comments indicate near term value sits in data layer automation: reconciliation, coding consistency, discrepancy detection, and safety surveillance that feeds humans faster.
Lilly argued FDA should select for the most mature oversight of AI, not the flashiest models. Lilly and Bayer independently proposed a DMF style pathway letting AI vendors file model documentation FDA can reference, similar to drug master files.
Who is affected
Clinical operations heads must upgrade data ops before buying decision layer AI. AI vendors selling to pharma need governance packages, not benchmark slides. CROs become integration hubs because RTCT success is an ecosystem problem spanning sites, sponsors, and regulators.
What to do next
Audit your trial stack for evidenced human review on AI assisted steps. If vendors cannot show change control and lineage, defer autonomous decision features even if models look strong on demos.
What to watch
Monitor FDA publication of final RTCT pilot selection criteria and named participants beyond AstraZeneca and Amgen proofs of concept. The next verifiable signal is a sponsor accepted into the broader pilot with public AI governance appendices.
Sources
- Primary. FDA, FDA Announces Major Steps to Implement Real Time Clinical Trials (28 April 2026). Proof of concept trials and RFI timeline.
- Secondary. Pharmaceutical Intelligence, FDA Contemplates Changes in Trial Design, Drug Development, and Use of AI in Clinical Trials (15 September 2026). Sponsor comment letter themes.
- Secondary. CASRAI summary (June 2026). Corroborates extended comment period and August selection target.